Clinical trial · no report yet · Phase 2
ASC2ESCALATE
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
- NCT05384587 ↗
- Active not recruiting
- Novartis Pharmaceuticals
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 2 | |
| X threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- asciminib
- Arms
- Asciminib · Experimental
- Enrollment
- 34
- Primary outcomes
- Percentage of participants who achieve Major Molecular Response (MMR) in the 2L setting
- Sponsor
- Novartis Pharmaceuticals
- Start
- Nov 11, 2022
- Primary completion
- Aug 13, 2025
- Results posted
- No
- Registry record
- NCT05384587 · updated Oct 14, 2025
Publications
linked from the registry- Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncol. 2024;20(38):3065-3075. doi: 10.1080/14796694.2024.2402680. Epub 2024 Oct 10. PubMed 39387441